Prot #EGL-6535-C-2202: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of CAL02 Administered Intravenously in Addition to Standard of Care in Subjects with Severe Community-Acquired Bacterial Pneumonia

Project: Research project

Project Details

StatusActive
Effective start/end date3/22/23 → 3/22/26

Funding

  • InClin, Inc. ((OE) Prot #EGL-6535-C-2202 // (OE) Prot #EGL-6535-C-2202)
  • Eagle Pharmaceuticals, Inc. ((OE) Prot #EGL-6535-C-2202 // (OE) Prot #EGL-6535-C-2202)